Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that on September 1, 2022, the Compensation Committee of Puma's Board.
NERLYNX was granted marketing authorization by the European Commission in 2018 for the extended adjuvant treatment of adult patients with early stage hormone receptor-positive HER2-overexpressed/amplified breast cancer and who are less than one year from completion of prior adjuvant trastuzumab-based therapy. In February 2020, NERLYNX was also approved by the FDA in combination with capecitabine for the treatment of adult patients with advanced or metastatic HER2-positive breast cancer who have received two or more prior anti-HER2-based regimens in the metastatic setting. Food and Drug Administration in 2017 for the extended adjuvant treatment of adult patients with early stage HER2-overexpressed/amplified breast cancer, following adjuvant trastuzumab-based therapy, and is marketed in the United States as NERLYNXยฎ (neratinib) tablets.
The collection is inspired by 70s football stars and their glamorous off-field lives, linking the flamboyant and extravagant approach of that decade's fashion ...
PUMA and Palomo Spain have developed a collection that explores team sports with a nostalgic edge and champions today's daring view of gender flexibility.
Your one-stop-shop for this week's fashion news to know.
German sportswear giant Puma is collaborating with the Spanish label, Palomo Spain.
Sportswear giant Puma has revealed a new collaboration with Palomo Spain consisting of a collection that merges team sports with today's take on gender...